CHINOOK SEEDERY Partners with Top MLB Prospect Bobby Witt Jr.
Bobby Witt Jr., shareholder and ambassador for Chinook Seedery
“When I tried Chinook for the first time, I was…
Browsing Tag
Chinook
Chinook Therapeutics Receives Orphan Drug Designation from European Commission for…
Enrollment ongoing in atrasentan pivotal phase 3 ALIGN study in IgAN and phase 2 AFFINITY study in proteinuric glomerular diseasesChinook expects to present data from the IgAN patient…
Chinook Therapeutics Presents Data from BION-1301 Phase 1/2 Trial in Patients with…
BION-1301 was well-tolerated and demonstrated rapid and sustained reductions in mechanistic biomarkers in patients with IgAN, including free APRIL, IgA and Gd-IgA1 levelsBION-1301…
Chinook Therapeutics Announces Upcoming Data Presentations and Investor Conference…
Additional data to be presented from the ongoing phase 1/2 study of BION-1301 in patients with IgA nephropathy, including biomarker and proteinuria reductions Several presentations on…
Chinook Therapeutics Provides Business Update and Reports Second Quarter 2021…
SEATTLE, Aug. 12, 2021 (GLOBE NEWSWIRE) -- Chinook Therapeutics, Inc. (Nasdaq: KDNY), a biopharmaceutical company focused on the discovery, development and commercialization of precision…
Chinook Therapeutics Presents BION-1301 Interim Phase 1/2 Data in Patients with IgA…
BION-1301 has been well-tolerated to date in patients with IgAN, with no serious adverse events (SAEs) or treatment discontinuations due to adverse eventsPharmacokinetics (PK) of BION-1301…